WEST LAFAYETTE, Ind., July 27, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today the pricing of the underwritten public offering of 5,809,931 shares of its common stock at a price to the public of $12.26 per share. 4,968,321 of these shares are being offered by Endocyte and 841,610 of these shares are being offered by an existing institutional shareholder. The offering was increased from the previously announced amount of 4,841,610 shares. Endocyte has granted the underwriters a 30-day option to purchase up to 871,489 additional shares to cover over-allotments, if any.
